While these diagnostic procedures are standard of care in breast cancer and gastric cancer, where ERBB2 is a more frequent target, mCRC patients are not regularly screened for ERBB2 alterations in most centers [10]. This evidence concerns the gene ERBB2 and breast carcinoma.